Announced details
Dry eye treatment
Efficacy was evaluated in a domestic Phase III clinical trial (Study 3-02). Specific efficacy figures: Not disclosed.
Mochida Pharmaceutical Co.,Ltd. discovered and out-licensed the product, while 千寿製薬株式会社 is responsible for its development, manufacturing and marketing. Takeda Pharmaceutical Company Limited markets the product.
Mochida Pharmaceutical Co.,Ltd.: Shinjuku-ku, Tokyo; President and Representative Director Naoyuki Mochida (持田直幸). 千寿製薬株式会社: Osaka City, Osaka; President and Representative Director Shuhei Yoshida (吉田周平). Overview of Takeda Pharmaceutical Company Limited: Not disclosed.
NHI drug price: ¥577.50 per 5 mL bottle
The company does not address Contract Value / Impact on Business Performance.
Dry Eye Disease Clinical Practice Guidelines (Clinical Practice Guidelines Development Committee, Dry Eye Research Society, 2019); Z. Pan et al. Invest Ophthalmol Vis Sci. 2011;52(1):485-93; P. Rozas et al. Pain 2016;157(6):1346-62, among others; Y. Sakane et al. JAMA Ophthalmol. 2013;131(10):1331-1338
| Item | Details |
|---|---|
| Names of Products / Services Covered | Abarept® 0.3% ophthalmic suspension (generic name: motigibatolep) |
| Counterparty | Takeda Pharmaceutical Company Limited; Mochida Pharmaceutical Co.,Ltd. |
| Counterparty overview | Mochida Pharmaceutical Co.,Ltd.: Shinjuku-ku, Tokyo; President and Representative Director Naoyuki Mochida (持田直幸). 千寿製薬株式会社: Osaka City, Osaka; President and Representative Director Shuhei Yoshida (吉田周平). Overview of Takeda Pharmaceutical Company Limited: Not disclosed. |
| Relationship with the Company | Mochida Pharmaceutical Co.,Ltd. discovered and out-licensed the product, while 千寿製薬株式会社 is responsible for its development, manufacturing and marketing. Takeda Pharmaceutical Company Limited markets the product. |
| Offering price | NHI drug price: ¥577.50 per 5 mL bottle |
| Launch date | 6 April 2026 (actual launch date) |
| Applicable area | Dry eye treatment |
| Quantitative Effects | Efficacy was evaluated in a domestic Phase III clinical trial (Study 3-02). Specific efficacy figures: Not disclosed. |
| Source | Dry Eye Disease Clinical Practice Guidelines (Clinical Practice Guidelines Development Committee, Dry Eye Research Society, 2019); Z. Pan et al. Invest Ophthalmol Vis Sci. 2011;52(1):485-93; P. Rozas et al. Pain 2016;157(6):1346-62, among others; Y. Sakane et al. JAMA Ophthalmol. 2013;131(10):1331-1338 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To improve the subjective symptoms and objective findings of patients with dry eye and contribute to improving their quality of life.